

**FORM PTO-1449  
INFORMATION DISCLOSURE STATEMENT**

INT'L SERIAL NO.	PCT/EP2004/004245
INT'L FILING DATE	April 21, 2004
APPLICANT	BRUTON et al.
GROUP	1624
EXAMINER	Coleman
ATTORNEY DOCKET NO.	PB60227USw

**U.S. PATENT DOCUMENTS**

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
/B.C./	1.	5,364,791	11/15/1994	Vegeto et al.			
/B.C./	2.	5,874,534	2/23/1999	Vegeto et al.			
/B.C./	3.	5,935,934	8/10/1999	Vegeto et al.			
/B.C./	4.	6,093,718	7/25/2000	Waterson et al.			
/B.C./	5.	2002/0115854	8/22/2002	Lam et al.			
/B.C./	6.	2003/0073718	4/17/2003	Barta et al.			

**FOREIGN PATENT DOCUMENTS**

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
/B.C./	7.	WO96/10022	4/4/1996	PCT			
/B.C./	8.	WO97/06802	2/27/1997	PCT			
/B.C./	9.	WO97/23462	7/3/1997	PCT			
/B.C./	10.	WO02/32893	4/25/2002	PCT			
/B.C./	11.	WO02/47679	6/20/2002	PCT			
/B.C./	12.	WO02/072570	9/19/2002	PCT			
/B.C./	13.	WO02/076925	10/3/2002	PCT			
**/B.C./	14.	WO03/062234	7/31/2003	PCT			abstract
/B.C./	15.	WO03/004480	1/16/2003	PCT			
/B.C./	16.	WO03/024928	3/27/2003	PCT			
/B.C./	17.	WO03/024929	3/27/2003	PCT			
/B.C./	18.	WO03/088967	10/30/2003	PCT			
/B.C./	19.	WO03/103669	12/18/2003	PCT			

Continue on page \_\_\_\_\_

**OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)**

/B.C./	20.	COTTET et al., Trifluoromethyl-Substituted Pyridines Through Displacement of Iodine by in situ Generated (Trifluoromethyl)copper, Eur. J. Org. Chem 327-330 (2002).
/B.C./	21.	COTTET et al., Recommendable Routes to Trifluoromethyl-Substituted Pyridine- and Quinolinecarboxylic Acids, Eur. J. Org. Chem 1559-1568 (2003).
/B.C./	22.	GIOVANNINI et al., "Effects of histamine H <sub>3</sub> receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia," Behavirural Brain Res. 104:147-155 (1999).
/B.C./	23.	GOODMAN et al., Desymmetrization of Dichloroazaheterocycles, Tetrahedon 55:15067-15070 (1999).
/B.C./	24.	LEURS et al., "Therapeutic potential of histamine H <sub>3</sub> receptor agonists and antagonists," TiPS 19:177-183 (May 1998).
/B.C./	25.	LOVENBERG et al., "Cloning and Funcnional Expression of the Human Histamine H <sub>3</sub> Receptor," Molecular Pharmacology 55:1101-1107 (1999).
/B.C./	26.	MICKELSON et al., Asymmetric Synthesis of 2,6-Methylated Piperazines, J. Org. Chem. 60:4177-4183 (1995).
/B.C./	27.	ONODERA and WATANABE, "Histamine H <sub>3</sub> Antagonists as Potential Therapeutics in the CNS," ed Leurs and Timmerman, pp255-267, Elsevier Science B.V. (1998).
/B.C./	28.	SAKAMOTO et al., Site-Selectivity in the Cyanation of 3-Substituted Pyridine 1 Oxides with Trimethylsilanecarbonitrile, Chem. Pharm. Bull. 33(2):565-571 (1985).
/B.C./	29.	SCHLICKER et al., "Modulation of neurotransmitter release via histamine H <sub>3</sub> heteroreceptors," Fundam Clin Pharmacol 8:128-137 (1994).

Continue on page \_\_\_\_\_

EXAMINER /Brenda Coleman/	DATE CONSIDERED 10/27/2008
---------------------------	----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

**\*\* Structures only**